Exicure

Exicure Interest Coverage

The Interest Coverage Ratio of Exicure (XCUR) as of Nov 16, 2026 is -1,935.00. In the previous year, Interest Coverage Ratio was -178.52 — a change of 983.89% (lower).

Interest Coverage

-1,935.00

YoY

983.89%

Last updated:

Interest Coverage Ratio of Exicure is 2024 -1,935.00 . Interest Coverage Ratio of Exicure was 2023 -178.52 . It decreases by 983.89% lower compared to the previous year.

The Exicure Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
-12.77 USD
Jan 1, 2018
-32.93 USD
Jan 1, 2019
-380.24 USD
Jan 1, 2020
-56.52 USD
Jan 1, 2021
-40.62 USD
Jan 1, 2022
-3.59 USD
Jan 1, 2023
-178.52 USD
Jan 1, 2024
-1,935.00 USD
The Exicure Interest Coverage history
YEARInterest CoverageYoY
-1,935.00+983.89%
-178.52+4,878.35%
-3.59-91.17%
-40.62-28.14%
-56.52-85.13%
-380.24+1,054.65%
-32.93+157.88%
-12.77-43.30%
-22.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exicure Stock analysis

What does Exicure do? Exicure, Inc. generates revenue through the development and commercialization of therapeutic products based on its Spherical Nucleic Acid (SNA) technology. The company focuses on immuno-oncology, genetic disorders, and other indications, with a pipeline including AST-008, XCUR-FXN, and XCUR17. AST-008 is a toll-like receptor 9 agonist designed to activate the innate immune system and induce anti-cancer responses, particularly when combined with checkpoint inhibitors. XCUR-FXN targets Friedreich’s ataxia (FA) in preclinical development, while XCUR17 is an SNA targeting IL-17RA mRNA for inflammatory disorders, Netherton syndrome, and hair loss disorders. The primary buyers of Exicure's products are pharmaceutical companies and healthcare providers seeking innovative treatments for complex conditions. The company's SNA technology enables therapeutic oligonucleotides to work across various cells and tissues, addressing unmet medical needs in immuno-oncology and genetic disorders. Commercial partnerships and licensing agreements are likely key revenue streams, though specific partners are not named in the business description. Exicure's product segments include immuno-oncology (AST-008), genetic disorders (XCUR-FXN), and inflammatory conditions (XCUR17). These segments target patients with specific diseases, such as cancer, Friedreich’s ataxia, and inflammatory disorders, where current treatments are limited. The company's focus on SNA technology differentiates its approach, aiming to unlock new therapeutic possibilities in these areas. Exicure is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exicure stock

Interest Coverage Ratio of Exicure is -1,935.00 in 2024.

Interest Coverage Ratio of Exicure changed from -178.52 to -1,935.00, representing a 983.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Exicure since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Exicure with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Exicure

All Key Metrics — Exicure